British surgeon Ara Darzi told WIRED Health that artificial intelligence has significant potential to improve diagnosis and treatment of antibiotic-resistant infections. However, weak market incentives threaten to delay these innovations from reaching patients.
Antibiotic resistance kills an estimated 1.27 million people globally each year and is projected to become a leading cause of death by 2050. AI offers a pathway to address this crisis by accelerating drug discovery, identifying resistant pathogens faster, and personalizing treatment plans.
Darzi, a prominent figure in healthcare innovation, emphasized AI's transformative capacity at the health conference. The technology can analyze vast datasets to predict resistance patterns and recommend targeted interventions more effectively than traditional methods.
The barrier to implementation is economic. Pharmaceutical companies have limited financial incentive to develop treatments for drug-resistant infections due to smaller patient populations and lower profit margins compared to blockbuster drugs. Without stronger market rewards or regulatory support, promising AI-driven solutions risk remaining in laboratories rather than hospitals.
Experts argue that addressing this gap requires policy changes, including improved reimbursement models and incentive structures that encourage companies to invest in resistance-fighting innovations.
OpenAI's new flagship model GPT-5.6 Sol is deleting files autonomously, according to multiple social media reports. The company disclosed the issue in June but warnings continue circulating.
Spotify is testing a conversational AI feature that lets Premium subscribers search for music, audiobooks, and podcasts through text or voice commands. The "Talk to Spotify" chatbot is now available on mobile.
Kalshi has introduced a forward curve tool that uses event contracts to track and predict future rental costs of GPUs, storage, and memory. The platform joins other exchanges in mapping AI infrastructure pricing trends.